Estimated global prevalence of genetic carriers of hereditary pheochromocytoma-paraganglioma syndrome in a large multiethnic genomic database
3
Issued Date
2025-09-30
Resource Type
eISSN
1479683X
Scopus ID
2-s2.0-105017869548
Pubmed ID
40974092
Journal Title
European Journal of Endocrinology
Volume
193
Issue
4
Start Page
412
End Page
420
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Endocrinology Vol.193 No.4 (2025) , 412-420
Suggested Citation
Charoenngam N., Wannachalee T. Estimated global prevalence of genetic carriers of hereditary pheochromocytoma-paraganglioma syndrome in a large multiethnic genomic database. European Journal of Endocrinology Vol.193 No.4 (2025) , 412-420. 420. doi:10.1093/ejendo/lvaf191 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112509
Title
Estimated global prevalence of genetic carriers of hereditary pheochromocytoma-paraganglioma syndrome in a large multiethnic genomic database
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
OBJECTIVES: To estimate the global prevalence of genetic carriers of pheochromocytoma-paraganglioma syndromes (PPGLs) in a large multiethnic genomic database. METHODS: We analyzed sequencing data from 807 162 unrelated individuals in the gnomAD v4.1 database, representing a global population of diverse ethnic ancestries. Eleven PPGLs-associated genes were examined: FH, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL, and MAX. Pathogenic or likely pathogenic variants (P/LP) were identified from ClinVar, while additional predicted deleterious variants were included based on loss-of-function annotations and splice prediction in silico tools. Prevalence estimates of genetic carriers were calculated by combining allele frequencies of qualifying variants. RESULTS: The prevalence of SDHA carriers was the highest when aggregating allele frequencies of both ClinVar P/LP and predicted deleterious variants (158.83 per 100 000), followed by NF1 (93.66 per 100 000) and FH (72.23 per 100 000), while VHL and MAX had the lowest prevalence. Substantial variation was observed across ancestries, with certain variants enriched in specific populations (eg, SDHC p.Tyr126Cys in non-Finnish Europeans; FH c.556-4A > G in East Asians). Carriers of SDHB, SDHC, and TMEM127 ClinVar P/LP or predicted deleterious variants were absent in the Middle Eastern group; SDHAF2 and SDHC were absent in the Ashkenazi Jewish group; and SDHAF2 and TMEM127 were absent in the Finnish group. Predicted deleterious variants significantly increased carrier estimates for SDHAF2, SDHD, and TMEM127. CONCLUSION: Our study highlights the variability in PPGL-associated mutation carrier prevalence across genes and ancestries. The findings underscore potential disparities in genetic risk that may not have been fully captured by clinical cohorts.